01541.HK
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
HKSE · Healthcare · Biotechnology · CN
HKD 3.15
−1.56%Year over year
Reported trailing growth
- Revenue
- +23.4%
- EBITDA
- +35.5%
- EBIT
- +34.3%
- EPS
- +32.1%
- Free cash flow
- +48.1%
- Operating cash flow
- +46.8%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +197.8%
- EBITDA
- +31.3%
- EBIT
- +29.5%
- Net income
- +32.6%
- EPS
- +39.3%
- Free cash flow
- -42.4%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026